Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer

Singapore Medical Journal

Volumn 51, Issue 11, 2010, Pages 871-875

  Kaushal, J ^a   Gupta, M C ^a   Kaushal, V ^b   Bhutani, G ^a   Dhankar, R ^b   Atri, R ^b   Verma, S ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Radiotherapy ^*  (India)

Author keywords

Acute emesis; Delayed emesis; Dexamethasone; Ondansetron; Palonosetron

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CYTOCARB; DEKSA; DEXAMETHASONE; DOCETAX; DOCETAXEL; EMESET; FLUOROURACIL; ONDANSETRON; PALONOSETRON; PALOSTAR; UNCLASSIFIED DRUG;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HEAD AND NECK CANCER; HUMAN; NAUSEA AND VOMITING; OPEN STUDY; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 78650065909     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003; 21:4077-80.
2. Abraham A, Sridhar N, Veeranjaneyulu A. Cancer chemotherapy and radiation induced emesis (CRIE): current and future therapeutic approaches. Indian J Pharmacol 2000; 32:256-68.
3. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329:1790-6.
4. Symth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 1991; 303:1423-6.
5. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18:163-73.
6. Roila F, Fatigoni S. New antiemetic drugs. Ann Oncol 2006; 17(Suppl 2): ii96-100
7. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 2007; 3:1009-20.
8. Eisenberg P, Figueroa-Vadillo J, Zamora R. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473-82.
9. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003; 4:2297-303.
10. Hickok JF, Roscoe JA, Morrow GR, et al. 5-hydroxytryptamine receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005; 6:765-72.
11. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338:483-7.
12. Boogaerts JG, Vanacker E, L. Seidel L, A. Albert A, Bardiau FM. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand 2000; 44:470-4.
13. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001; 111(Suppl 8A):106S-112S.
14. Pasricha PJ. Treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the Pharmacological Basis Of Therapeutics. 10th ed. New York: McGraw Hill, 2001: 983-1008.
15. The gastrointestinal tract. In: Rang HP, Dale MM, Ritter JM, Flower RJ, eds. Rang and Dale's Pharmacology. 6th ed. London: Churchill Livingstone Elsiever, 2007: 385-96.
16. McQuaid KR. Drugs used in the treatment of gastrointestinal disorders. In: Katzung BG, ed. Basic and Clinical Pharmacology. 10th ed. Boston: McGraw Hill, 2007: 1009-40.
17. Sanger GJ. The pharmacology of antiemetic agents. In: Andrews PLR, Sanger GJ, eds. Emesis in Anticancer Therapy: Mechanism and Treatment. London: Chapman & Hall Medical, 1993: 179-210.
18. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17:1441-9.